JP2023506787A5 - - Google Patents

Info

Publication number
JP2023506787A5
JP2023506787A5 JP2022535631A JP2022535631A JP2023506787A5 JP 2023506787 A5 JP2023506787 A5 JP 2023506787A5 JP 2022535631 A JP2022535631 A JP 2022535631A JP 2022535631 A JP2022535631 A JP 2022535631A JP 2023506787 A5 JP2023506787 A5 JP 2023506787A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
pharmaceutical product
product according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506787A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064662 external-priority patent/WO2021119523A1/en
Publication of JP2023506787A publication Critical patent/JP2023506787A/ja
Publication of JP2023506787A5 publication Critical patent/JP2023506787A5/ja
Pending legal-status Critical Current

Links

JP2022535631A 2019-12-11 2020-12-11 Parp阻害薬と組み合わせたatr阻害薬の使用 Pending JP2023506787A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946876P 2019-12-11 2019-12-11
US62/946,876 2019-12-11
PCT/US2020/064662 WO2021119523A1 (en) 2019-12-11 2020-12-11 Use of atr inhibitors in combination with parp inhibitors

Publications (2)

Publication Number Publication Date
JP2023506787A JP2023506787A (ja) 2023-02-20
JP2023506787A5 true JP2023506787A5 (cg-RX-API-DMAC7.html) 2023-12-18

Family

ID=76316464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535631A Pending JP2023506787A (ja) 2019-12-11 2020-12-11 Parp阻害薬と組み合わせたatr阻害薬の使用

Country Status (12)

Country Link
US (2) US20210177856A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072551A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023506787A (cg-RX-API-DMAC7.html)
KR (1) KR20220128350A (cg-RX-API-DMAC7.html)
CN (1) CN115103677A (cg-RX-API-DMAC7.html)
AU (1) AU2020402108A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011426A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164203A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001540A1 (cg-RX-API-DMAC7.html)
IL (1) IL293810A (cg-RX-API-DMAC7.html)
MX (1) MX2022007163A (cg-RX-API-DMAC7.html)
WO (1) WO2021119523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
JP2024522736A (ja) * 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド がん治療のためのparp阻害剤と組み合わせたatr阻害剤の使用
EP4504208A1 (en) * 2022-04-07 2025-02-12 Repare Therapeutics Inc. Methods of using atr inhibitors
KR20250023494A (ko) * 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2024164089A1 (en) * 2023-02-09 2024-08-15 Repare Therapeutics Inc. Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
CN117159725B (zh) * 2023-04-06 2024-07-05 上海交通大学医学院附属仁济医院 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法
WO2024243078A1 (en) * 2023-05-19 2024-11-28 Leapfrog Bio, Inc. Hsp90 inhibitors for the treatment of cancer
JP2026518747A (ja) * 2023-05-23 2026-06-09 ザ フランシス クリック インスティテュート リミテッド Alt陽性がんの治療のための標的

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
EP3585365B1 (en) * 2017-02-24 2021-08-25 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors with parp inhibitors
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체

Similar Documents

Publication Publication Date Title
JP2014528464A5 (cg-RX-API-DMAC7.html)
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP2020125349A5 (cg-RX-API-DMAC7.html)
CN103402519B (zh) 肿瘤治疗剂
JP2022520061A5 (cg-RX-API-DMAC7.html)
JP2021534168A5 (cg-RX-API-DMAC7.html)
JP2021534158A5 (cg-RX-API-DMAC7.html)
JP2016505512A5 (cg-RX-API-DMAC7.html)
JP2019535746A5 (cg-RX-API-DMAC7.html)
JP2018510191A5 (cg-RX-API-DMAC7.html)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2023531709A5 (cg-RX-API-DMAC7.html)
JP2015515961A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2015524450A5 (cg-RX-API-DMAC7.html)
JP2026053473A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
JP2023553534A5 (cg-RX-API-DMAC7.html)
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
JP2014524449A5 (cg-RX-API-DMAC7.html)
JP2021534160A5 (cg-RX-API-DMAC7.html)
JP2024515061A5 (cg-RX-API-DMAC7.html)
KR20090025247A (ko) 방사선 치료 증강제
JP2016502540A5 (cg-RX-API-DMAC7.html)
EP4346765A2 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
JP2018528949A5 (cg-RX-API-DMAC7.html)